Optimizing Patient Outcomes in Diabetic Retinopathy


Activity Information

Credits: 1.00 AMA PRA Category 1 Credit(s)
Launch Date: January 21, 2020
Expiration Date: January 21, 2021


Charles C Wykoff, MD, PhD
Director of Research, Retina Consultants of Houston
Deputy Chair for Ophthalmology, Blanton Eye Institute
Associate Clinical Professor of Ophthalmology, Weill Cornell Medical College Houston Methodist Hospital
Houston Texas

Eric W Schneider, MD
Tennessee Retina, Partner and Vitreoretinal Surgeon
Nashville Tennessee

William W Li, MD
President and Chief Executive Officer, The Angiogenesis Foundation
Cambridge, MA


  1. Identify and compare current treatment pathways for diabetic retinopathy patients and diabetic macular edema and their impact on patient outcomes.     
  2. Develop consensus on factors responsible for differences in referral pathways for diabetic retinopathy patients and conceptualize patient referral guidelines.
  3. Synthesize key outstanding questions regarding timing of patient referral from optometrist to ophthalmologist in diabetic retinopathy.     
  4. Present recommendations for actions to improve diabetic retinopathy patient referrals to achieve optimal patient outcomes.


Content and educational strategies have been designed to facilitate behavior change in ophthalmologists, primary care physicians, residents and fellows, physician assistants, nurse practitioners, optomistrists, and all health care providers (HCPs) who care for patients at risk for diabetes and associated retinal disease.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedicusCME and the Angiogenesis Foundation.  MedicusCME is accredited by the ACCME to provide continuing medical education for physicians.


MedicusCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



It is the policy of MedicusCME to identify and resolve any potential conflicts of interest of anyyone who may be in a position to influence or control the content of an education activity, to assure balance, independence, objectivity and scientific rigor in all of its accredited activities. All faculty and planners are expected to disclose all financial relationships with a commercial interest within the past twelve months.


Dr. Wykoff acknowledges receipt of consulting fees from Acuela, Alimera Sciences, Allegro, Bayer, DORC, EyePoint, Fosun, ONL Therapeutics, Opthea, Optos, Outlook Therapeutics, Oxurion and PolyPhotonix Takeda for his participation on their respective scientific advisory boards.  He acknowledges receipt of research support from Aerie Pharmaceuticals, Aldeyra Therapeutics, Gemini Therapeutics, Graybug Vision, IONIS Pharmaceuticals, Neurotech, Opthea, Outlook Therapeutics, Samsung, Senju Pharmaceuticals and Xbrane Biopharma; and of both consulting fees and research support from Adverum, Aerpio, Allergan, Apellis, Chengdu Kanghong, Clearside Biomedical, Genentech/Roche, Iveric Bio (formerly Ophthotech), Kodiak, Novartis, Optos, Recens Medical, Regenxbio, Regeneron and Santen. Additionally, he owns stock in Regeneron.

All other planners, faculty, authors and presenters of this accredited activity deny any personal or financial relationships with ACCME-defined commercial entities that may constitute any real or perceived conflict of interest.


By participating in all course content and learning strategies, and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™.

    Read the learning objectives and faculty disclosures.
    Participate in the activity.
    Complete the post-test and activity evaluation.
    Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
    All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

COURSE FORMAT/MEDIUM: Internet Activity (Enduring Material)


This activity is supported by an independent educational grant from Regeneron Pharmaceuticals.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


William W. Li, MD
President and Chief Executive Officer, The Angiogenesis Foundation

Eric W Schneider, MD
Tennessee Retina, Partner and Vitreoretinal Surgeon
Nashville Tennessee

Charles C. Wykoff, MD, PhD, FACS
Clinical Associate Professor of Ophthalmology, Weill Cornell Medical College
Physician, Surgeon, Director of Research, Retinal Consultants of Houston, PA Director of Clinical
Research and Vice-President, Greater Houston Retina Research Foundation
Houston, Texas

Brad H. Feldman, MD
Ophthalmologist and Surgeon, Wills Eye Hospital
Clinical Instructor in Ophthalmology, Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, Pennsylvania

Steven Haimowitz, MD
President, RealCME

Carol Pashman, MS, RN
President, MedicusCME

Jeff McRae, MS
Grants Administrator, The Angiogenesis Foundation


Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.        

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above